KR20160084606A - Method for Producing Ketoconazole Tablets - Google Patents

Abstract

The present invention relates to a manufacturing method of a ketoconazole tablet. The ketoconazole tablet is manufactured by performing a wet granulation process of ketoconazole powder, a first excipient, and a second excipient so that the weight ratio of the ketoconazole powder to the first excipient becomes 3.0-3.4, and the weight ratio of the second excipient to the first excipient becomes 0.07-0.14. Accordingly, a highly concentrated ketoconazole tablet can be obtained so an effective dose of ketoconazole can be administered to a pet by single oral administration. Furthermore, a cross-shaped perforated line is formed on the surface of the ketoconazole tablet during a tablet making process so a user can control dosage to one-fourth to three-fourths of a tablet according to needs. According to the present invention, the ketoconazole tablet obtained by the manufacturing method can be easily administered to a pet, and the dosage of the ketoconazole tablet is easily controlled so the treatment of mycosis in a pet can be effectively performed.

Description

METHOD FOR PRODUCING KETOCONAZOLE TABLETS

The present invention relates to a method for preparing ketoconazole tablet used as an antifungal agent for pets.

Ketoconazole is an imadazole fungicide and has been used for the treatment of various systemic fungal infections including candidiasis, candidiasis, bacteremia, coccidiosis fungus, histoplasmosis, pigment fungus, and paracoxidase fungus. The antifungal effect of ketoconazole is to inhibit the cytochrome P450 enzyme system of the fungus and to block the synthesis of ergosterol, an essential component of the fungal cell wall. It blocks T-cell proliferation and 5-lipoxygenase activity, It shows a

However, ketoconazole is known to cause hepatotoxicity in rat hepatocyte or mouse hepatocyte, and its use is restricted. Particularly, when oral administration to dogs, the half-life lethal dose (LD50) of ketoconazole is 937 mg / kg bw, and in the case of parenteral administration (intravenous administration), it is reported to be 424 mg / kg bw.

For this reason, if the ketoconazole is administered to a pet such as a dog or a cat, it should be administered in small doses several times and continuously administered for a sufficient period of time to treat fungal infections.

However, when conventional ketoconazole is prepared by tableting, when it contains a large amount of ketoconazole powder, it is possible to prepare tablets by mixing a larger amount of excipient than ketoconazole to prepare the formulation.

US Patent Publication No. 2009-0298848 discloses that the ratio of ketoconazole to other ingredients such as excipient is 1: 1 by weight, and U.S. Patent No. 6040307 also discloses that the content of ketoconazole is about 100 to 200 mg Mixed tablets are disclosed.

In order to orally administer the ketoconazole formulation to pets, one or several tablets must be administered at once in accordance with the symptoms. Therefore, it is difficult to administer orally and it takes time for administration.

Therefore, the ketoconazole preparation for oral administration to pets is required to have a property of containing a high concentration of ketoconazole contained in one tablet so that oral administration can be completed with only one dose.

At the same time, the dosage of ketoconazole should be readily adjustable as needed.

US Patent Publication No. 2009-0298848 U.S. Patent No. 6040307

The method for preparing ketoconazole of the present invention has been developed in order to solve the problems of the prior art as described above. It provides a method for producing a tablet containing ketoconazole at high concentration, whereby an effective amount of ketoconazole is administered to a pet It is another object of the present invention to provide a method for preparing ketoconazole tablets which can easily adjust the dosage to a pet by allowing the tablets to be divided easily through incision.

In order to achieve the above object, the present invention provides a method for preparing ketoconazole tablet, which comprises preparing ketoconazole powder and first and second excipients by wet granulation, wherein the weight ratio of ketoconazole to the first excipient is 3.0 to 3.4, And the weight ratio of the second excipient is 0.08 to 0.14.

In addition, the first excipient of the present invention is methyl cellulose, particularly, an aqueous solution of hydroxypropylmethylcellulose, and the second excipient is preferably corn starch.

The wet granulation of the present invention is a process for preparing a mixture by mixing the ketoconazole powder, the excipient, the binder, the disintegrant, and the lubricant; Granulating the mixture to produce a semi-finished product; A sizing step of drying and forming the semi-finished product; And a tableting step of tableting the formed semi-finished product.

In addition, the process for preparing the mixture may include a primary mixing step of mixing the ketoconazole powder and the second excipient to prepare a first mixture; A second mixing step of mixing the first mixture with a lubricant and a first excipient to prepare a second mixture; A binder solution preparation process for dissolving the binder in a solvent; And a homogenization step of adding the binder solution to the secondary mixture and stirring to prepare a tertiary mixture.

In addition, the tableting step includes a step of forming a cross-shaped line on the surface of the tablets, thereby making it easy to cut tablets so that the dosage of ketoconazole can be easily adjusted as needed.

The content of ketoconazole contained in the ketoconazole tablet of the present invention is 60 to 70% by weight based on the total weight of the tablet, and a large amount of the ketoconazole ingredient may be contained in one tablet.

Since the ketoconazole tablet obtained by the preparation method of the present invention contains a high concentration of ketoconazole in one tablet, an effective amount of the drug can be administered to a pet by oral administration once, and a cross-shaped incision is formed on the surface of the tablet The dosage can be adjusted to 1/4 to 3/4 of the tablet as needed, so that it can be easily administered to pets and can effectively treat fungal infections.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart illustrating a method of preparing a ketoconazole tablet according to an embodiment of the present invention. FIG.

Reducing the amount of excipients and increasing ketoconazole makes it difficult to produce tablets, so a practical and practical solution to obtaining tablets containing ketoconazole at a high concentration is desperately needed.

In view of the above circumstances, it is an object of the present invention to provide a process for producing tablets containing ketoconazole at a high concentration represented by the formula (I).

As a result of intensive studies to solve the above problems, the present inventors have found that a tablet containing ketoconazole at a high concentration can be prepared by mixing and kneading the ketoconazole powder, the first and second excipients, the binder and the lubricant Thus completing the present invention.

Hereinafter, the present invention will be described in detail.

The production process of the present invention is characterized by preparing ketoconazole tablets by wet granulation.

Wherein the wet granulation includes a step of preparing a mixture of ketoconazole powder, first and second excipients, a binder and a lubricant; Granulating the mixture to produce a semi-finished product; A sizing step of drying and forming the semi-finished product; And a tableting step of tableting the formed semi-finished product.

In order to contain ketoconazole at a high concentration in the present invention, it is necessary to establish process conditions capable of controlling the relative amount of ketoconazole powder to the excipient, which can be achieved by strictly controlling the preparation process of the mixture.

That is, the process for preparing a mixture in the present invention includes a primary mixing step of mixing a ketoconazole powder and a second excipient to prepare a first mixture; A second mixing step of mixing the first mixture with a lubricant and a first excipient to prepare a second mixture; A binder solution preparation process for dissolving the binder in a solvent; And a homogenization process in which the binder solution is added to the secondary mixture and stirred to prepare a tertiary mixture.

The ketoconazole tablet obtained by the preparation method of the present invention is prepared by adding the ketoconazole to the first excipient in a weight ratio of 3.0 to 3.4, preferably 3.1 to 3.3, the weight ratio of the second excipient to the first excipient is 0.08 to 0.14, To 0.12, it is possible to obtain tablets containing a high concentration of ketoconazole compared with the conventional tablets.

The ketoconazole powder used in the preparation of the tablet of the present invention is preferably a fine powder having a particle diameter of not less than 90% by weight, preferably not more than 850 占 퐉, more preferably not more than 500 占 퐉, particularly preferably not more than 150 占 퐉.

In the present invention, the particle diameter is a value measured by a dry laser diffractometer (e.g., Mastersizer 2000, Malvern Instruments Ltd.).

The lower limit of the particle diameter of the ketoconazole powder is not particularly limited. In general dry pulverization such as jet mill, 90 wt% or more is several tens of 탆, but such fine powder can be used favorably.

When 90 wt% or more of ketoconazole is 850 mu m or less, it is advantageous in that the dissolution rate of the compound (I) is high.

(1) Mixture manufacturing process

In the mixture manufacturing process of the present invention, the ketoconazole powder is mixed with the second excipient.

Examples of the second excipient include lactose, starch, corn starch, crystalline cellulose, minute sugar, granular sugar, mannitol, light anhydrous silicic acid and L-cysteine. The second excipient may be used alone or in combination of two or more. The content of the second excipient in the tablet of the present invention is preferably 0.1 to 3.0% by weight, preferably 1.0 to 2.5% by weight, particularly preferably 1.8 to 2.1% by weight.

When the first mixture is prepared by mixing the ketoconazole powder and the second excipient, the lubricant and the first excipient are added to the first mixture and mixed. The mixing can be efficiently performed by using a cooperating unit.

The first excipient includes, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone-vinyl acetate copolymer, cellulose ethyl ester, enteric polymer (for example, hydroxypropylmethylcellulose phthalate, Cellulose acetate phthalate, carboxymethyl cellulose, etc.), a water-insoluble polymer (e.g., aminoalkyl methacrylate copolymer, methacrylic acid copolymer, etc.), and the like. Methyl cellulose, especially hydroxypropyl methylcellulose Is preferably used.

If necessary, plasticizers such as polyethylene glycol, dibutyl sebacate, diethyl phthalate, triacetin, triethyl citrate, and stabilizers may be used.

The amount of the first excipient is preferably 0.01 to 90% by weight, more preferably 0.1 to 80% by weight, and most preferably 2 to 50% by weight.

Examples of the lubricant include magnesium stearate, talc, and the like.

The amount of the lubricant is preferably 0.1 to 3.0% by weight, preferably 1.0 to 2.5% by weight, and particularly preferably 1.8 to 2.1% by weight.

The lubricant and the first excipient are added to the first mixture and mixed to prepare a second mixture.

In addition, a binder solution for dissolving the binder in a solvent is prepared, and the binder solution is added to the secondary mixture and stirred to prepare a tertiary mixture.

Examples of the binder include sucrose, gelatin, arabian rubber powder, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, polyvinylpyrrolidone (povidone K29 / 32) , Dextrin, and the like. These binders may be used alone or in combination of two or more. The content of the binder in the tablet of the present invention is preferably 0.01 to 30% by weight, more preferably 0.03 to 10% by weight.

The binder may be dissolved in a solvent, and the solvent may be water or an organic solvent such as methanol, ethanol, propanol, and butanol. The content of the solvent is preferably 0.1 to 50% by weight, and more preferably 10 to 40% by weight.

When the binder solution is put into the second mixture, it is required to be rapidly stirred to homogeneously mix. This is to prevent the homogeneity of the mixture from deteriorating due to the evaporation of the solvent.

(2) semi-finished product manufacturing process

The semi-finished product manufacturing process of the present invention comprises the steps of granulating the mixture to produce a semi-finished product; A sizing step of drying and forming the semi-finished product; And is performed through a tableting process of setting the set semi-finished product.

The granulation process is carried out using a 1.2 mm sieve, and powdery solid compositions are prepared by pulverization by spray drying, freeze drying, vacuum drying or the like through a drying process. The above solid composition is again formulated using a 1.2 mm sieve to obtain a semi-finished product for tableting.

When necessary, an anti-aggregation agent, an antistatic agent, and the like may be added. Examples of the anti-aggregation agent include anti-caking agents such as hydrous silicon dioxide, light silicic acid anhydride and magnesium aluminometasilicate, saccharides such as lactose, sugar alcohols such as mannitol and trehalose, and the antistatic agent includes talc, , Light silicic anhydride, and the like.

In addition, the drying step may be used for fluid bed assembly, electric flow assembly, and centrifugal power assembly. It is also possible to dissolve the wettability improver in an appropriate solvent or to spray the partially dissolved suspension directly as a binder solution to obtain a granulated product.

In this case, the wettability improver includes polyoxyethylene alkyl ethers, polyethylene glycol fatty acid esters, polyoxypropylene alkyl ethers, polypropylene glycol fatty acid esters, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, poly Nonionic surfactants such as glycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, glycerin mono fatty acid esters, alkylpolyglucosides, polyoxyethylene polyoxypropylene block polymers and alkanolamides; Amphoteric surfactants such as alkyldimethylaminoacetic acid betaine, amidopropyldimethylaminoacetic acid betaine, amido amino acid salts and alkyliminodiacetic acid salts; Alkyl sulfates, alkyl ether sulfuric acid ester salts, alkyl ether sulfuric acid ester salts, olefin sulfonic acid salts, acylmethyltaurine salts, acylglutamates, acylglycin salts, acyl sarcosinates, acylisethionates, alkyl ether carboxylates, amido ether sulfuric acid esters Anionic surfactants such as salts and alkylphosphoric acid ester salts; Cationic surfactants such as alkyltrimethylammonium chloride, dialkyldimethylammonium chloride and the like; But are not limited to, bile acids and salts thereof, soaps and fatty acids and salts thereof, oils, glycerin fatty acid esters, enamines, chelating agents, phenothiazine, fatty acids derivatives of carnitine or peptides, azones, Ethoxymethylenemalonate, the products of the Mailrod reaction, block copolymers and biodegradable polymers, chitosan and chitosan derivatives. Among these, surfactants (amphoteric surfactants, anionic surfactants, cationic surfactants), hydrophilic polymers, cyclodextrin derivatives, and cholic acid derivatives are preferable, and surfactants are particularly preferable. Among the surfactants, anionic surfactants are preferable, long-chain alkyl (preferably 10 to 20 carbon atoms) sulfate is more preferable, and sodium lauryl sulfate is most preferable. Also, the sodium lauryl sulfate here is a single substance. The wettability improver may be used in a combination of two or more species.

In addition, in the above pulverization, the wax or the like heated and melted as the solvent is used in addition to the above spray drying, freeze drying, vacuum drying, etc., and the liquid composition which is dissolved or partially dissolved in the wax is solidified by returning to a room temperature It is also possible to pulverize the solidified product. It is also possible to add wax or the like newly heated and melted to the crushing suspension obtained in this step and return to the room temperature to solidify the crushed suspension to crush the solidified product.

The blending ratio of the wettability improver is not particularly limited, but it is preferably 0.00001 to 100 parts by weight, more preferably 0.00001 to 10 parts by weight, particularly preferably 0.0001 to 10 parts by weight, based on 1 part by weight of the target substance for improving wettability. 5 parts by weight. When the objective substance for improving wettability and the wettability improver are used in a suitable solvent or as a suspension in which some of them are dissolved, the solid concentration in the liquid is not particularly limited, but 0.01 to 1000% (wt / wt) , More preferably 0.1 to 500% (wt / wt), and most preferably 1 to 100% (wt / wt). Here, the solid content concentration is calculated by dividing the sum of the weight of the wettability improving agent and the wettability improving agent contained in the solution or suspension by the weight of the liquid.

As an example of surface modification as a method for improving wettability other than the blending of the wettability improver, there is a method of dry-assembling a surface of a target such as a wettability improving agent and a wettability improver by a tumbler mixer or the like, , A fluidized bed assembly, an electric flow assembly, and a centrifugal motorized granulator.

In addition, post-mixing may be performed after addition of magnesium stearate before tableting.

The tableting process of the present invention can be tableted through a rotary tablet machine. If desired, film-coated tablets may be obtained by spraying the film coating liquid through a film coater to the tableted tablet.

Further, in the case of continuous tableting, hardening oil may be added to reduce the load caused by the friction between the tableting machine and the punches. In addition, other conventional additives, fragrances, coloring agents and the like may be appropriately selected and added, mixed, and then tableted to prepare tablets.

Since the tableting machine of the present invention uses a punch formed with projections for forming a cross-shaped line in the tablets, it is possible to easily produce separable tablets. Since the tablets can be easily divided by hand, the amount of tablets can be controlled to 1/4 to 3/4, depending on the dosage.

In addition, the content of ketoconazole contained in the ketoconazole tablet of the present invention is 60 to 70% by weight based on the total weight of the tablet, and a large amount of the ketoconazole ingredient may be contained in one tablet.

Hereinafter, the present invention will be described in more detail with reference to preferred embodiments of the present invention. However, the following examples are only for the understanding of the present invention, and the scope of the present invention should not be reduced or limited.

The raw materials used in this example are ketoconazole (Zhejiang East-Asia Pharmaceutical Co., LTD), polyvinyl pyrrolidone (Povidone K29 / 32) (HJ Nanhang Industrial Co., LTD), corn starch (Samyang Genex) Magnesium (FACIASIA PACIFIC PTE LTD), and hydroxypropylmethylcellulose (Ming Tal).

14.709 kg of ketoconazole and 0.515 kg of corn starch were mixed to prepare a first mixture, and 0.515 kg of magnesium stearate, 4.53 kg of hydroxypropylmethylcellulose and the first mixture were mixed using a coater to prepare a second mixture. In this example, the weight ratio of ketoconazole to the first excipient is 3.23, and the weight ratio of the second excipient to the first excipient is 0.11.

Separately, 1.765 kg of polyvinylpyrrolidone was dissolved in 3.971 kg of ethanol to prepare a polyvinylpyrrolidone solution.

The polyvinylpyrrolidone solution was poured into the second mixture and stirred rapidly to obtain a third mixture.

The third mixture was granulated using a sieve of 1.2 mm to obtain a semi-finished product. The semi-finished product was placed in a fluid spray dryer (IL SUNG MACHINE MFG. CO.) And dried until the drying loss was 2.0 to 3.0%.

The dried semi-finished product was again sieved using a sieve of 1.2 mm, and then the resultant was compressed to be 96% or more of the weight of the manufactured unit.

At this time, an appropriate amount of magnesium stearate was added before crushing, followed by post-mixing.

The tablet was made with a KILAN & C Type RUI 42517-1170 tablet machine, and a cross-shaped protrusion was formed in the punch and a cross-shaped line was formed by the tablet. The static pressure was 0.7 ton / cm 2.

A tablet of ketoconazole was prepared by inserting a cruciform line on the surface of the tablets which had been completely tableted. The prepared ketoconazole tablet contained an average weight of 200 mg of ketoconazole per 300 mg tablets.

The ketoconazole tablet was prepared in the same manner as in Example 1 except that the weight ratio of ketoconazole to the first excipient was 3.15 and the weight ratio of the second excipient to the first excipient was 0.12.

 [Comparative Example 1]

The ketoconazole tablet was prepared in the same manner as in Example 1, except that the weight ratio of ketoconazole to the first excipient was 1.04 and the weight ratio of the second excipient to the first excipient was 0.16.

 [Comparative Example 2]

The ketoconazole tablet was prepared in the same manner as in Example 1 except that the weight ratio of ketoconazole to the first excipient was 3.55 and the weight ratio of the second excipient to the first excipient was 0.07.

Next, the collapse tests for the four kinds of tablets obtained in Examples 1 and 2 and Comparative Examples 1 and 2 were conducted with a predetermined number of specimens (N = 5). In the collapse test, water was measured by a collapse tester using a test liquid. The results are shown in Table 1.

Hardness of tablet (kg)
Decay time (minutes) medium Actual value

Example 1



7



3.0

3.2 3.0 2.9 3.1 2.9

Example 2



6



3.0

2.8 2.9 3.2 3.1 3.0

Comparative Example 1



7



9.3

8.9 9.2 8.3 9.8 10.5

Comparative Example 2



4



3.9

3.8 3.9 4.2 3.7 4.1

Based on the above results, it has been found that the tablets prepared by the method for preparing ketoconazole tablets of the present invention can be effectively used as tablets for pets because of their high hardness and short time to collapse. In addition, since it is a tablet containing a high concentration of ketoconazole, it was confirmed that an effective dose can be administered even once.

 [Experimental Example 1]

In order to confirm the use stability of the ketoconazole preparations prepared in the present invention, three doses of the clinical application amount and clinical application amount of the dog (female) were administered for 4 weeks, And biochemical changes were investigated.

The test was orally administered to twelve female dogs (Nara Biotech Co., Ltd.) (twice weekly and body weight range: 6 to 8 months, 10.30.7 kg at the time of tablet administration) twice daily for 4 weeks. The daily dose of ketoconazole tablet was 0, 15, 45 mg / kg bw / day.

One tablet of ketoconazole is 300 mg, and the effective amount of ketoconazole is 200 mg. When the dose is converted into the effective amount, it corresponds to 0, 10, 30 mg / kg bw / day.

Ketoconazole refinement was repeatedly administered twice daily for 4 weeks to observe the occurrence of death and drowsiness, clinical symptoms, weight change, feed intake, hematology, and blood biochemistry. After the end of the observation period, autopsy was carried out for each individual, and histologic examination was performed for abnormal organ.

 The test results are as follows.

1) Mortality

No deaths were observed during the test period.

2) Clinical symptoms

From the second day after administration, transient kidney was observed in the control group, the clinical dose group (the dose of ketoconazole effective amount 10 mg / kg bw / day) and the clinical triple dose group (ketoconazole effective dose 30 mg / kg bw / day) Was not a peculiar symptom.

3) Weight change

There was no significant difference in body weight between the test substance administration group and the control group until the 28th day of the test substance administration period.

4) Dietary intake and feed intake

Negative and feed intake were not different between the treatment groups.

5) Hematological analysis

The hematological changes of the control group, the clinical dose group (Ketoconazole effective ingredient 10 mg / kg bw / day) and the clinical triple dose group (Ketoconazole effective ingredient 30 mg / kg bw / day) Changes in RBC, MCH, and MCHC were observed, but no dose-dependent or normal range of drug-induced changes were observed.

6) Serum biochemical analysis

(ALT), albumin (ALB), triglyceride (TG), total protein (T-PRO), alanine-transaminase (ALT), aspartate-transaminase Serum biochemical changes of total bilirubin (T-BIL), glucose (GLU), total cholesterol (T-CHO), blood urea nitrogen (BUN) and creatinine (CRE) However, there was a statistically significant increase in ALT and a decrease in T-CHO in the triple dose group compared with the control group during the drug administration period, but there was no biological significance as a result within the normal range Respectively.

7) Autopsy findings

No visual abnormalities were observed in all groups after the observation period.

8) Histopathological findings

Histopathologic findings of liver, kidney, adrenal, and ovary in the control group, the clinical dose group, and the triple dose group were not observed.

9) Long term weight

All the organ weights of the clinical dose group and the clinical triple dose group were not different from the control group.

From the results of the experiment, it was found that ketoconazole supplements were given orally to the pets for 28 days orally in the clinical dose group (10 mg / kg bw / day of active ingredient of ketoconazole) and 3 times of the dose of triple dose (ketoconazole effective ingredient 30 mg / kg bw / day) No toxicity was observed.

Therefore, it was judged that there was no adverse effect even when ketoconazole solution was repeatedly orally administered for 4 weeks at a dose of 3 times the clinical dose (30 mg / kg bw / day based on the active ingredient, 45 mg / kg bw / day based on the product weight).

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, Accordingly, the true scope of protection of the present invention should be construed according to the following claims, and all technical ideas within the scope of the claims should be construed as being included in the scope of the present invention.

Claims (6)

Wherein the weight ratio of ketoconazole to the first excipient is from 3.0 to 3.4 and the weight ratio of the second excipient to the first excipient is from 0.08 to 0.14. 2. The method according to claim 1, wherein the ketoconazole powder, the first excipient and the second excipient are wet- ≪ / RTI > The method according to claim 1,
Wherein the first excipient is methylcellulose and the second excipient is starch. The method according to claim 1,
Wherein the wet granulation comprises a step of preparing a mixture of the ketoconazole powder, the first excipient, the second excipient, the binder and the lubricant;
Granulating the mixture to produce a semi-finished product;
A sizing step of drying and forming the semi-finished product;
And a tableting step of tableting the formed semi-finished product. The method of claim 3,
The mixture preparation process includes a primary mixing step of mixing a ketoconazole powder and a second excipient to prepare a first mixture;
A second mixing step of mixing the first mixture with a lubricant and a first excipient to prepare a second mixture;
A binder solution preparation process for dissolving the binder in a solvent;
Wherein the binder solution is added to the secondary mixture and stirred to prepare a tertiary mixture. The method of claim 4,
Wherein the tableting step comprises a step of forming a cruciform line on the surface of the tablet. The method according to claim 1,
Wherein the content of ketoconazole contained in the ketoconazole tablet is 60 to 70% by weight based on the total weight of the tablet.

Images